Abbott Sues India’s Lupin Over Cholesterol Generic
This article was originally published in PharmAsia News
U.S.-based Abbott Laboratories has filed a suit to stop India's Lupin from selling a generic of Abbott's cholesterol drug Niaspan (niacin). Abbott said in its suit it has seven U.S. patents on the drug, the earliest not set to expire until 2013. The American company, which acquired the drug when it bought Kos Pharmaceuticals in 2006, filed the patent suit in two separate federal courts. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.